SNY Jan 2024 43.000 call
| Previous close | 13.90 |
| Open | 13.90 |
| Bid | 10.10 |
| Ask | 14.50 |
| Strike | 43.00 |
| Expiry date | 2024-01-19 |
| Day's range | 13.90 - 13.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 58 |
ZacksRegeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
GlobeNewswirePress Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors Approval of the financial statements for the fiscal year 2022Distribution of a cash dividend of €3.56 per share, with payment as of June 1st, 2023Board composition: Frédéric Oudéa becomes Independent Director and Chairman of the Board Paris, May 25, 2023. The Combined General Shareholders’ Meeting of Sanofi was held on May 25, 2023, under the chairmanship of Serge Weinberg. The General Meeting approved
Motley Fool2 Bear Market Defying Stocks to Buy in May
This group of companies includes Sanofi (NASDAQ: SNY) and Axsome Therapeutics (NASDAQ: AXSM). France-based Sanofi is a biotech giant with a diversified portfolio of medicines and vaccines, although it is perhaps best known for being one of the leaders in the insulin market. The company grabbed headlines in this space earlier this year when it decided to cut the price of its top-prescribed insulin product, Lantus, by 78% and limit out-of-pocket costs to $35.
- GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placeboDupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 w
PR NewswireSanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
Sanofi (NASDAQ: SNY) is pleased with the United States Supreme Court's ruling in Amgen v. Sanofi et. al. The decision unanimously affirms the United States Federal Circuit Court's opinion that is favorable to Sanofi and Regeneron.
- GlobeNewswire
Sanofi: Information concerning the total number of voting rights and shares – April 2023
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,521,494,572 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
- GlobeNewswire
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s consistent and high efficacy against infant hospitalizations due to RSVData presented at ESPID add to the body of evidence demonstrating nirsevimab’s protection against RSV-related lower respiratory tract disease (LRTD) and confirm its favorable safety profile in multi-country, real-world conditions Paris, May 12, 2023. New data from the HARMONIE P
ZacksDenali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
ZacksRegeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
- GlobeNewswire
Sanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS
COMBINED GENERAL MEETING OF MAY 25, 2023 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday May 25, 2023 at 2:30 p.m. (CET) at the Palais des Congrès – Grand Amphithéâtre – 2, place de la Porte Maillot – 75017 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the websi
ZacksSNY or LLY: Which Is the Better Value Stock Right Now?
SNY vs. LLY: Which Stock Is the Better Value Option?
ZacksIs a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
Motley FoolSanofi (SNY) Q1 2023 Earnings Call Transcript
SNY earnings call for the period ending March 31, 2023.
ZacksEli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised
Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.
ZacksSanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong
Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.
- Zacks
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.
- GlobeNewswire
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
Sanofi completes acquisition of Provention Bio, Inc. Paris, April 27 2023. Sanofi announced today the completion of its acquisition of Provention Bio, Inc. (“Provention Bio”). The acquisition adds TZIELD (teplizumab-mzwv), an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi’s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile. Olivier CharmeilExecutive Vice President, General Medicines, Sanofi
- GlobeNewswire
Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
Strong Q1 growth driven by Specialty Care, Vaccines and CHC Paris, April 27, 2023 Q1 2023 sales growth of 5.5% at CER and business EPS(1) growth of 11.9% at CER Specialty Care grew 18.3% driven by Dupixent® (€2,316 million, +39.7%) and Rare Disease Vaccines up 15.2% reflecting recovery of Booster and Travel vaccines and COVID vaccine shipments in Europe General Medicines sales lower (-11.4%) mainly due to Lantus® and divestments, core assets growing 1.6%CHC sales of €1,495 million increased by 1
IPO-Edge.comCustomized Treatments in Modern Medicine: Hear from Thirty Madison President and CFO Live from the NYSE Floor
IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with senior management from Thirty Madison . The in-person interview featured President Michelle Carnahan and […]
- Zacks
Is a Surprise Coming for Sanofi (SNY) This Earnings Season?
Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- GlobeNewswire
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc. Paris, France – April 26, 2023 – Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Provention Bio, Inc. (“Provention Bio”, NASDAQ: PRVB) has expired. On March 24, 2023, Sanofi commenced a cash tender offer (the “Offer”) to purchase all outstanding shares of common stock of
ZacksAstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
Zacks4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
ZacksSanofi (SNY) is a Great Momentum Stock: Should You Buy?
Does Sanofi (SNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZacksSanofi (SNY) Stock Moves -0.45%: What You Should Know
In the latest trading session, Sanofi (SNY) closed at $55.47, marking a -0.45% move from the previous day.